Brasília – The Brazilian Association of Fine Chemical, Biotechnology and Specialties Industries (Abifina) held the 16th International Seminar on Patents, Innovation and Development (SIPID), gathering experts from government, industry, and academia to discuss innovation policies, legal certainty, and national production.

Participants warned about the risks of judicial patent term extensions (Patent Term Adjustment, PTA), not provided under Brazilian law, and their potential impact on SUS costs. The government reaffirmed its commitment to reduce patent examination times to two years by 2026 through the use of artificial intelligence.

Source: Panorama Farmacêutico

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com